INMB Nasdaq Investor Presentation April 2024 Innate Immune Therapeutics

Investor presentation for Inmunology (INMB), a clinical-stage immunology company developing two biologic therapeutic platforms targeting innate immune dysfunction. The company's pipeline includes candidates for Alzheimer's disease, prostate cancer, and other neurological conditions and cancers, with clinical data expected in 2024-2025.